Oric Pharmaceuticals (NASDAQ:ORIC) Shares Up 11.6% – What’s Next?

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) shares were up 11.6% during mid-day trading on Thursday . The company traded as high as $8.30 and last traded at $8.3340. Approximately 969,787 shares traded hands during trading, a decline of 48% from the average daily volume of 1,861,488 shares. The stock had previously closed at $7.47.

Trending Headlines about Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: ORIC selected rinzimetostat 400 mg QD as the recommended Phase 3 (RP3D) dose in combination with darolutamide for the Himalayas?1 registrational trial, moving the program toward a global Phase 3 start (initiation expected 1H 2026). GlobeNewswire Release
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $25 price target, signaling continued analyst conviction and a sizeable upside thesis from current levels. TickerReport
• Neutral Sentiment: Wedbush trimmed its price target from $20 to $17 but kept an “outperform” rating — still positive relative to the market price but a pullback in near?term target. Benzinga
• Neutral Sentiment: Unusually large options flow: ~2,266 call contracts traded (a >2,000% rise vs. average), which can amplify intraday moves and reflects speculative/leveraged bullish interest. (No single-direction guarantee — could reflect hedging or directional bets.)
• Negative Sentiment: Market reaction driven by dose?related safety/side?effect signals in the Phase 1b rinzimetostat + darolutamide data; outlets reported steep intraday drops after the update. Investors appear focused on tolerability at higher doses despite moving to Phase 3. Yahoo Finance
• Negative Sentiment: Additional coverage and sell?side commentary highlighted the safety concerns and valuation risk, contributing to follow?on selling and volatility. Investing.com

Analyst Ratings Changes

A number of brokerages have issued reports on ORIC. Citigroup upped their price objective on shares of Oric Pharmaceuticals from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Wall Street Zen raised Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Piper Sandler started coverage on Oric Pharmaceuticals in a research report on Wednesday, January 7th. They set an “overweight” rating and a $22.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Oric Pharmaceuticals in a report on Thursday. Finally, Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.90.

Oric Pharmaceuticals Stock Performance

The business’s 50 day moving average is $11.62 and its two-hundred day moving average is $11.31. The firm has a market capitalization of $829.96 million, a PE ratio of -5.44 and a beta of 1.36.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. As a group, equities research analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Insider Activity

In other news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total value of $702,520.00. Following the completion of the transaction, the chief financial officer directly owned 68,148 shares in the company, valued at approximately $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.82% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Orbimed Advisors LLC increased its holdings in shares of Oric Pharmaceuticals by 305.0% in the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after purchasing an additional 2,742,475 shares during the period. Paradigm Biocapital Advisors LP purchased a new position in Oric Pharmaceuticals during the fourth quarter worth about $19,642,000. State Street Corp increased its stake in Oric Pharmaceuticals by 77.1% in the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after acquiring an additional 1,854,458 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Oric Pharmaceuticals by 48.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after acquiring an additional 1,525,445 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Oric Pharmaceuticals by 3,646.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock valued at $13,555,000 after acquiring an additional 1,299,799 shares during the last quarter. 95.05% of the stock is owned by institutional investors.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.